View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter’s Weekly Newsletter
Nir Barzilai, Director of the Institute for Aging Research at the Albert Einstein College of Medicine, is back for his third appearance on The Drive. In this episode, Nir divulges insights into lifespan and healthspan through the lens of his extensive research on centenarians as well as the latest from the TAME trial (Targeting/Taming Aging with Metformin), a multi-center study investigating the concept that the multi-morbidities of aging can be delayed in humans. He discusses common gene variants found in centenarians, important pathways for longevity, and ultimately what we can learn from centenarians about extending lifespan while also trying to improve healthspan. Additionally, Nir goes into depth on metformin as a longevity tool for humans, including studies with positive and negative results. He discusses the impact metformin can have on exercise for both strength training and cardiovascular training, as well as future research facilitated by data from the TAME Trial. He also touches on epigenetic clocks and concludes with his take on the usefulness of NAD precursors as a potential gero-protective agent.
We discuss:
Connect With Peter on Twitter, Instagram, Facebook and YouTube
#195 - Freedom, PTSD, war, and life through an evolutionary lens | Sebastian Junger
#194 - How fructose drives metabolic disease | Rick Johnson, M.D.
#193 - AMA #31: Heart rate variability (HRV), alcohol, sleep, and more
#192 - COVID Part 2: Masks, long COVID, boosters, mandates, treatments, and more
#191 - Revolutionizing our understanding of mental illness with optogenetics | Karl Deisseroth M.D., Ph.D.
#190 - Paul Conti, M.D.: How to heal from trauma and break the cycle of shame
#189 - COVID-19: Current state of affairs, Omicron, and a search for the end game
Iñigo San Millán, Ph.D.: Zone 2 Training and Metabolic Health (Ep. #85 Rebroadcast)
#188 - AMA #30: How to Read and Understand Scientific Studies
#187 - Sam Apple: The Warburg Effect—Otto Warburg’s cancer metabolism theory
#186 - Patrick Radden Keefe: The opioid crisis—origin, guilty parties, and the difficult path forward
#185 - Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we assess risk
Rick Johnson, M.D.: Metabolic Effects of Fructose (Ep. #87 Rebroadcast)
#184 - AMA #29: GLP-1 Agonists—The Future of Treating Obesity?
#183 - James Clear: Building & changing habits
#182 - David Nutt: Psychedelics & Recreational Drugs
#181 - Robert Gatenby, M.D.: Viewing cancer through an evolutionary lens and why this offers a radically different approach to treatment
#180 - AMA #28: All things testosterone and testosterone replacement therapy
#179 - Jeremy Loenneke, Ph.D.: The science of blood flow restriction—benefits, uses, and what it teaches us about the relationship between muscle size and strength
#178 - Lance Armstrong: The rise, fall, and growth of a cycling legend
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Huberman Lab
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.